Mississauga, ON -- (SBWIRE) -- 12/29/2015 -- AllPennyStocks.com Media, Inc. (http://www.AllPennyStocks.com/) announces its latest article titled "Amarantus BioScience Requests Rare Pediatric Disease and Orphan Drug Designations from US FDA."
Companies mentioned in this article include iShares NASDAQ Biotechnology Index (ETF) (NASDAQ:IBB) and Amarantus BioScience Holdings Inc. (OTCQX:AMBS).
The biotech sector is headed for a higher 2015 finish despite struggling in the second half of this year. The iShares NASDAQ Biotechnology Index (ETF) (NASDAQ:IBB) is up nearly 13% for 2015. But in the second half of 2015, the sector has fallen almost 5%.
The two main concerns investors have with the biotech sector are increasing scrutiny from politicians about the pricing strategy for drugs and high valuations. With the U.S. election in 2016, the pricing strategy of drug companies will come under further scrutiny. This is likely to keep the whole sector under pressure.
This morning, one biotechnology company came out with some important news. Amarantus BioScience Holdings Inc. (OTCQX:AMBS) is a biotechnology company focused on the development of products for Regenerative Medicine, Neurology and Orphan Diseases. The company today announced that it has requested Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation ('ODD) from the Food and Drug Administration (FDA) to treat GCMN with Engineered Skin Substitute (ESS).
The full version of this article can be found at:
AllPennyStocks.com is focused on the small-cap / penny stock market and has become a reputable name in the investment community. AllPennyStocks.com runs a Canadian and US site to provide investors in Canada as well as the United States with informative and unique content and information. AllPennyStocks.com runs daily technical penny stocks to watch, has a daily market write-up, provides company spotlights, runs unique most active pages strictly for penny stocks trading on the TSX, TSX Venture, NASDAQ and OTC BB, and much more information for the average investor.
AllPennyStocks.com also runs an email newsletter that aims to uncover stocks that are still under the radar of most investors. Criteria AllPennyStocks.com looks for includes strong revenues, a seasoned management, innovative business plans, among many others. AllPennyStocks.com also looks for companies that announce breaking news, recent 52-week highs/lows, technical breakouts, and other favorable corporate information.
Investors are encouraged to subscribe to the AllPennyStocks.com FREE e-mail newsletter and see what tens of thousands of other investors have already been receiving since 1999. Investors can receive their free newsletter subscription by clicking here: http://www.allpennystocks.com/aps_common/newsletter_free.asp.
AllPennyStocks.com Media, Inc.
Peter Szafranski -- President
Phone: (905) 361-5680
Websites: http://www.allpennystocks.com / http://www.bullishinvestor.com
Note: AllPennyStocks.com has not received compensation for carrying the above-mentioned company; a full disclaimer can be viewed here: http://www.allpennystocks.com/aps_common/disclaimer.asp.